Carolyn F. Deacon

Carolyn F. Deacon

Associate Professor


  1. Published

    A review of dipeptidyl peptidase-4 inhibitors. Hot topics from randomised controlled trials

    Deacon, Carolyn F., 2018, In: Diabetes, Obesity and Metabolism. 20, Suppl. 1, p. 34-46

    Research output: Contribution to journalReviewResearchpeer-review

  2. Published

    Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus

    Deacon, Carolyn F., 2020, In: Nature Reviews Endocrinology. 16, 11, p. 642-653

    Research output: Contribution to journalReviewResearchpeer-review

  3. Published

    What do we know about the secretion and degradation of incretin hormones?

    Deacon, Carolyn F., 2005, In: Regulatory Peptides. 128, 2, p. 117-24 7 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Published

    Therapeutic strategies based on glucagon-like peptide 1.

    Deacon, Carolyn F., 2004, In: Diabetes. 53, 9, p. 2181-9 8 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Published

    Dipeptidyl peptidase IV inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective.

    Deacon, Carolyn F. & Holst, Jens Juul, 2002, In: Biochemical and Biophysical Research Communications. 294, 1, p. 1-4 3 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  6. Published

    Potential of liraglutide in the treatment of patients with type 2 diabetes

    Deacon, Carolyn F., 2009, In: Vascular Health and Risk Management (Online). 5, 1, p. 199-211 12 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  7. Published

    MK-431 (Merck).

    Deacon, Carolyn F., 2005, In: Current Opinion in Investigational Drugs. 6, 4, p. 419-26 7 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  8. Published

    Immunoassays for the incretin hormones GIP and GLP-1

    Deacon, Carolyn F. & Holst, Jens Juul, 2009, In: Best Practice & Research: Clinical Endocrinology & Metabolism. 23, 4, p. 425-32 7 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  9. Published

    Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes.

    Deacon, Carolyn F., 2007, In: Expert Opinion on Investigational Drugs. 16, 4, p. 533-45 12 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  10. Published

    Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes

    Deacon, Carolyn F. & Holst, Jens Juul, Jan 2010, In: Expert Opinion on Investigational Drugs. 19, 1, p. 133-40 8 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

ID: 9220